[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer-patients\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer-patients":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,77,108,130,153,176,197,223,248,278,305,335],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100612469","cancer-survivors-program-100612469",false,"NCT07253987","Cancer Survivors Program","Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer","SURV-QoL","Inclusion Criteria:\n\n* The patient understands the information provided and agrees to participate in the study.\n* Age 18 years or older.\n* Histologically confirmed invasive breast cancer or invasive prostate cancer.\n* Completion of the acute phase of curative oncological therapy:\n\n  * for breast cancer: curative surgery performed + completed neoadjuvant\u002Fadjuvant chemotherapy and completed adjuvant radiotherapy, if indicated\n  * for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy\n* The patient is available for follow-up within 12 months of enrollment in the study.\n\nExclusion Criteria:\n\n* Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4\u002F6i, PARPi, T-DM1), (iii) adjuvant immunotherapy)\n* Neoadjuvant\u002Fadjuvant therapy did not include chemotherapy (breast cancer).\n* Recurrence of cancer\n* Metastatic disease\n* History of other primary malignancy (except for non-melanoma skin cancer)","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.",[27,28],"Prostate Cancer Patients","Breast Cancer Patients",[30,31,32,33,34],"cancer survivors","breast cancer","prostate cancer","neo-\u002Fadjuvant chemotherapy","quality of life","RECRUITING","2026-06-10",{"date":38,"type":39},"2026-06-11","ACTUAL",{"date":41,"type":39},"2025-05-05",{"date":43,"type":21},"2026-12-31",{"name":45,"class":46},"Masaryk Memorial Cancer Institute","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100590237","the-effect-of-cold-salt-water-foot-bath-on-the-development-of-chemotherapy-induced-peripheral-neuropathy-100590237","NCT06964802","The Effect of Cold Salt Water Foot Bath on the Development Of Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Women aged 18 and over.\n* Conscious\n* Speaking and understanding Turkish\n* The diagnosis was breast cancer\n* Those who will receive paclitaxel chemotherapy\n* These are patients who answered 'no' to the 'A' section of the CIPNAT scale\n\nExclusion Criteria:\n\n* Responding to the vibration test (if the practitioner does not feel the vibration when the patient says they feel the vibration, it means that neuropathy is present)\n* Feeling pressure in one or none of the three areas on the plantar surface of the foot according to the monofilament test\n* Previous chemotherapy-associated peripheral neuropathy\n* Diagnosed with diabetes\n* Open wounds or skin ulcers on the foot\n* With peripheral and central nervous system disease\n* Peripheral vascular disease,\n* Patients with bone or soft tissue metastases","FEMALE",{"count":56,"type":21},30,[24],"This prospective, randomised, controlled study was designed to evaluate the effectiveness of salt and unsalted cold water foot baths in preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients receiving paclitaxel. The study's sub-objectives were to minimise the development of CIPN, reduce its severity and incidence of symptoms, and minimise its impact on daily life and activities.\n\nHypothesis(es):\n\nH1: Salt cold water foot bath affects the development of chemotherapy-induced peripheral neuropathy.\n\nH2: There is an effect of unsalted cold water foot bath on the development of chemotherapy-induced peripheral neuropathy.\n\nH3: The effects of salt and unsalted cold water foot baths on the development of chemotherapy-induced peripheral neuropathy.\n\nH4: Salt and unsalted cold water foot baths are more effective than standard clinical care in the development of chemotherapy-induced peripheral neuropathy.\n\nResearchers will compare the salt cold water with the unsalted cold water, unsalted cold water and control group to determine whether the salt cold water has an effect on CIPN.\n\nThe experimental group and active comparator participants will continue the application for 12 cycles (12 weeks) of paclitaxel. The application will be applied by researcher Tuba Eryiğit. In addition, before each application for 12 weeks, the severity of CIPN, its effect on daily life and grade will be evaluated.\n\nThe control group will continue clinical routine care applications for 12 cycles (12 weeks). In addition, the severity of CIPN, its effect on daily life and grade will be evaluated before each treatment in the same way as the experimental groups.",[28,60,61],"Chemotherapy Induced Peripheral Neuropathy (CIPN)","Paclitaxel-induced Peripheral Neuropathy",[63,64,65,66,67],"Chemotherapy-Induced Peripheral Neuropathy","Cold Salt Water","Foot Bath","Breast Cancer","Paclitaxel","2026-04-13",{"date":70,"type":39},"2026-04-16",{"date":72,"type":39},"2025-06-01",{"date":74,"type":21},"2026-07-01",{"name":76,"class":46},"Tuba Eryiğit",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100620264","phase-2-huaier-granule-and-proteinuria-100620264","NCT07355361","Huaier Granule and Proteinuria","Multicenter, Randomized, Parallel-Controlled Clinical Trial on Huaier Granule for Proteinuria Associated With Immunotherapy and Anti-Angiogenic Therapy in Breast Cancer Patients","N093","Inclusion Criteria:\n\n* \\*\\*Inclusion Criteria\\*\\*\n\n  1. Female patients aged 18-75 years.\n  2. Histopathologically confirmed diagnosis of breast cancer.\n  3. Currently receiving or having a prior history of immunotherapy and\u002For anti-angiogenic therapy.\n  4. First-time detection of proteinuria on urinalysis, graded as +, ++, or +++.\n  5. 24-hour urinary protein quantification between 0.15g and 3.5g (exclusive).\n  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n  7. Karnofsky Performance Status (KPS) score ≥70.\n  8. No prior treatment with Huaier Granule within one month before enrollment.\n  9. Life expectancy of at least 6 months.\n  10. Willingness to voluntarily participate in the study and provision of signed informed consent.\n\nExclusion Criteria:\n\n* \\*\\*Exclusion Criteria\\*\\*\n\n  1. Known history of chronic kidney disease (eGFR \\\u003C60 ml\u002Fmin\u002F1.73m²) or diabetic nephropathy.\n  2. Proteinuria attributed to other diseases, including but not limited to primary renal disease, hypertension, urinary tract infection, systemic lupus erythematosus, or multiple myeloma.\n  3. Current use of ACEI\u002FARB medications (unless the dosage has been stable for ≥4 weeks prior to enrollment).\n  4. Known allergy, contraindication, or specific precaution to any component of Huaier Granule.\n  5. Women who are pregnant, breastfeeding, or planning to conceive.\n  6. Concurrent participation in any other clinical trial investigating medications for proteinuria.\n  7. Any other condition that, in the judgment of the investigator, would make the patient unsuitable for participation in this study.","75 Years",{"count":87,"type":21},120,[89],"PHASE2","The goal of this clinical trial is to learn if adding Huaier Granule to standard care can treat proteinuria (excess protein in the urine) in adult female breast cancer patients (aged 18-75) who developed this condition as a side effect of their immunotherapy or anti-angiogenic cancer treatment.\n\nThe main question it aims to answer is:\n\n\\* Does the addition of Huaier Granule to standard care improve the effectiveness of proteinuria treatment after 8 weeks?\n\nResearchers will compare the group receiving standard care plus Huaier Granule to the group receiving standard care alone to see if the combination is more effective at reducing protein levels in the urine.\n\nParticipants will:\n\n* Be randomly assigned to one of the two study groups.\n* Continue their prescribed anti-cancer therapy (immunotherapy or anti-angiogenic therapy).\n* Receive standard medical care for proteinuria from a kidney specialist.\n* If in the experimental group, take Huaier Granule orally, three times a day.\n* Attend clinic visits every 4 weeks for up to 24 weeks for check-ups and tests, including urine and blood tests.",[92,28],"Proteinuria",[94,95,96,97],"proteinuria","Immunotherapy","Anti-angiogenic therapy","Breast cancer patients","NOT_YET_RECRUITING","2026-01-13",{"date":101,"type":39},"2026-01-21",{"date":103,"type":21},"2026-01-15",{"date":105,"type":21},"2028-06-15",{"name":107,"class":46},"Fudan University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":47},"100603395","breast-cancer-bras-study-breast-cancer-biomechanics-of-radiotherapy-and-surgery-100603395","NCT07135960","Breast Cancer BRAs Study (Breast Cancer Biomechanics of Radiotherapy And Surgery)","Breast Cancer BRAs Study (Breast Cancer Biomechanics of Radiotherapy And Surgery): The Effects of Breast Surgery and Radiotherapy on the Breast Biomechanics and Breast Support Requirements of Women Treated for Breast Cancer.","Inclusion Criteria:\n\n* Female\n* 18 years of age or above\n* Early or locally advanced breast cancer classified as B5a or B5b (radical treatment intent)\n* Unilateral breast cancer (contralateral breast used as control)\n* Receiving or has received breast cancer surgery\n* +\u002F- Adjuvant radiotherapy\n* Able to travel to the University of Portsmouth Breast biomechanics laboratory\n* Participant has capacity to consent.\n\nExclusion Criteria:\n\n* Metastatic breast cancer diagnosis\n* \\\u003C 2 weeks post-operative\n* \\\u003C 4 weeks post-radiotherapy\n* Active post-operative breast infection\n* Requirement of ongoing breast dressings\n* Previous breast surgery to contralateral breast\n* Bilateral breast cancer\n* Epilepsy (due to strobe on 3D scanner)\n* Pregnancy or \\\u003C6 weeks post-partum\n* Breastfeeding\n* Rockwood Frailty score \\>5 (or those unable to ambulate un-aided)\n* Requiring interpreter.",{"count":116,"type":21},45,"OBSERVATIONAL","This study, delivered by Portsmouth Hospitals University NHS Trust in conjunction with the Research Group in Breast Health at the University of Portsmouth \\[1\\], aims to assess whether it is possible to test breast biomechanics in women who have had surgery with or without radiotherapy for the treatment of breast cancer.",[28],"2025-08-20",{"date":122,"type":39},"2025-08-22",{"date":124,"type":39},"2025-02-06",{"date":126,"type":21},"2026-01-31",{"name":128,"class":129},"Portsmouth Hospitals NHS Trust","OTHER_GOV",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":150,"leadSponsor":151,"locationsCount":47},"100596154","rhomboid-intercostal-block-with-sub-serratus-plane-block-versus-erector-spinae-block-100596154","NCT07041762","Rhomboid Intercostal Block With Sub-Serratus Plane Block Versus Erector Spinae Block","Analgesic Efficacy of Rhomboid Intercostal Block With Sub-Serratus Plane Block Versus Erector Spinae Block in Breast Cancer Surgery","RISS-ESPB","Inclusion Criteria:\n\n* Female breast cancer patients undergoing Modified Radical Mastectomy (MRM)\n\nASA physical status II or III\n\nAge between 18 and 65 years\n\nBody Mass Index (BMI) \\> 20 kg\u002Fm² and \\\u003C 35 kg\u002Fm²\n\nExclusion Criteria:\n\n* Patient refusal\n\nASA physical status IV\n\nAge \\\u003C18 years or \\>65 years\n\nBMI \\\u003C 20 kg\u002Fm² or \\> 35 kg\u002Fm²\n\nKnown allergy or contraindication to local anesthetics or opioids\n\nHistory of psychological disorders or chronic pain\n\nContraindications to regional anesthesia (e.g., coagulopathy, local infection, peripheral neuropathy)\n\nSevere respiratory, cardiac, hepatic, or renal disease","65 Years",{"count":140,"type":21},80,[24],"This study compares two nerve block techniques-Rhomboid Intercostal with Sub-Serratus Plane Block versus Erector Spinae Plane Block-for pain relief after breast cancer surgery. It aims to determine which method provides better postoperative pain control, reduces opioid use, and improves recovery in patients undergoing modified radical mastectomy at the National Cancer Institute, Cairo University.",[28],[145],"erector spinae block","2025-06-25",{"date":148,"type":39},"2025-06-27",{"date":72,"type":39},{"date":74,"type":21},{"name":152,"class":46},"Cairo University",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":47},"100595832","efficacy-and-safety-of-prepectoral-prosthesis-immediate-one-stage-breast-reconstruction-versus-two-stage-expanderprosthesis-reconstruction-in-postoperative-adjuvant-radiotherapy-breast-cancer-patients-a-prospective-single-center-cohort-study-100595832","NCT07037576","Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander\u002FProsthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study","Inclusion Criteria:\n\n1. women aged 18 to 70；\n2. Newly diagnosed breast cancer patients showing no evidence of distant metastasis on clinical examination and diagnostic workup；\n3. adjuvant radiotherapy is required;\n4. Patients scheduled to undergo nipple-sparing mastectomy (NSM) or skin-sparing mastectomy (SSM) with immediate prepectoral implant-based reconstruction (via open, endoscopic, or robotic approach) require adjuvant radiotherapy AFTER permanent implant placement; OR Patients scheduled for NSM\u002FSSM with two-stage tissue expander\u002Fimplant reconstruction (with expander placement in either submuscular or prepectoral plane) receive radiotherapy WITH the tissue expander in situ, followed by exchange for permanent implant ≥6 months post-radiotherapy (expander position: submuscular\u002Fprepectoral acceptable; surgical approach: open\u002Fendoscopic\u002Frobotic acceptable);\n5. Patients are eligible regardless of whether mesh is used in the reconstruction surgery;\n6. Patients with severe breast ptosis are eligible;\n7. During the study observation period, lipofilling is permitted on the affected breast and symmetrization procedures on the contralateral breast in both cohorts;\n8. ECOG performance status 0-1;\n9. Patients receiving neoadjuvant chemotherapy (NACT) are eligible;\n10. Bilateral breast reconstruction is permitted;\n11. No smoking history OR smoking cessation ≥4 weeks prior to enrollment;\n12. Investigator-confirmed protocol compliance capability;\n13. Concurrent participation in other interventional\u002Fnon-interventional trials is allowed if deemed non-interfering by the investigator;\n14. Voluntarily participate and sign the informed consent form after comprehensive understanding.\n\nExclusion Criteria:\n\n1. Stage IV (metastatic) breast cancer;\n2. No prior radiotherapy post-mastectomy;\n3. History of ipsilateral chest wall\u002Faxillary radiation therapy;\n4. Immunodeficiency, poorly controlled diabetes (HbA1c \\>7%), or active tobacco use;\n5. Inflammatory breast cancer (cT4d);\n6. Autologous-based breast reconstruction or delayed reconstruction;\n7. Severe cardiopulmonary\u002Fhepatic\u002Frenal comorbidities contraindicating surgery\u002Fradiotherapy (ASA class ≥III);\n8. Psychiatric disorders precluding independent BREAST-Q completion;\n9. Pregnancy or lactation;\n10. Documented history of protocol non-adherence;\n11. Life-limiting comorbidities interfering with treatment OR investigator-determined ineligibility.","70 Years",{"count":161,"type":21},104,"Prospective Evaluation of the Efficacy and Safety of Prepectoral Immediate One-Stage Prosthetic Breast Reconstruction Versus Two-Stage Expander\u002FProsthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients",[28],[165,166,167],"Breast cancer","Breast reconstruction surgery","Radiotherapy","2025-06-17",{"date":146,"type":39},{"date":171,"type":39},"2025-05-20",{"date":173,"type":21},"2028-03-30",{"name":175,"class":129},"Henan Cancer Hospital",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":159,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":47},"100595829","evaluation-of-the-effectiveness-and-safety-of-laparoscopic-assisted-mastectomy-with-preservation-of-nipple-and-areola-immediate-one-step-breast-reconstruction-with-pectoral-muscle-prosthesis-and-patch-and-simultaneous-autologous-fat-transplantation-100595829","NCT07037537","Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation","To Evaluate the Efficacy and Safety of Laparoscopic-assisted Nipple-areola-sparing Mastectomy Plus Pectoral Anterior Prosthesis Plus Mesh Immediate One-step Breast Reconstruction Plus Concurrent Autologous Fat Grafting: a Prospective, Single-centre, Single-arm Study","Inclusion Criteria:\n\n1. Women aged 18 to 70 years old;\n2. In the first diagnosis of unilateral breast cancer patients, the maximum diameter of invasive tumor is ≤ 5cm, and there is no requirement for tumor size of carcinoma in situ in principle;\n3. Patients undergoing preventive mastectomy are not allowed to be included in the study;\n4. Clinical examination and auxiliary examinations suggest that the tumor is confined to the mammary gland and has not invaded the nipple areola complex, skin, or chest wall;\n5. Clinical axillary lymph node negative (clinical physical examination and imaging suggest negative axillary lymph nodes; for suspected positive axillary lymph nodes, fine needle aspiration or hollow needle biopsy is required to confirm negative);\n6. Sentinel lymph node biopsy negative;\n7. Patients with low load positive axillary lymph nodes (isolated tumor cells, micro or macro metastases), but exempted from adjuvant radiotherapy after surgery;\n8. Patients who are not suitable for breast conserving surgery or who are unwilling to undergo breast conserving surgery and plan to undergo laparoscopic assisted mastectomy with preservation of the nipple and areola, as well as immediate one-step breast reconstruction with a breast prosthesis combined with a chest muscle prosthesis and simultaneous fat transplantation; If frozen pathology or routine pathology indicates a positive posterior margin of the nipple, it is allowed to remove the nipple, but the areola must be preserved;\n9. The volume of the prosthesis is less than 500cc;\n10. During the observation period of the study, the affected side may consider re fat injection, but symmetrical surgery is not allowed on the healthy side;\n11. ECOG score 0-1 points;\n12. New adjuvant chemotherapy patients are allowed to be enrolled;\n13. No smoking history or quitting smoking for at least 4 weeks;\n14. The researcher determines that they are able to comply with the research protocol;\n15. Those who participate in other clinical trials (including intervention or non intervention studies) at the same time and are judged by the researchers to not affect the study protocol can be enrolled normally;\n16. After obtaining sufficient information, voluntarily participate and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Specialized physical examination and\u002For auxiliary examination suggest that the tumor involves the nipple areola complex (including Paget's disease) or the skin;\n2. Double breast cancer;\n3. Bilateral breast reconstruction patients;\n4. Patients who have undergone fat injection, breast augmentation with implants, and breast reduction surgery in the past;\n5. Patients with incomplete immune function, poor control of diabetes and active smoking;\n6. Patients with severe breast sagging;\n7. Breast cup size ≥ E;\n8. Accept two-step breast reconstruction using dilators\u002Fprostheses, autologous breast reconstruction, and breast reconstruction performed through open surgery;\n9. Patients who have previously received and\u002For received postoperative radiotherapy for the reconstruction site or chest wall;\n10. Patients who plan to undergo symmetrical surgery on the healthy breast during the visit period;\n11. Patients with mental illnesses or abnormalities who are expected to be unable to independently complete the BREAST-Q scale;\n12. Pregnant and lactating patients;\n13. Poor compliance, unable to conduct relevant examinations and follow ups according to the trial requirements;\n14. Suffering from serious accompanying diseases or other comorbidities that may interfere with planned treatment, or any other circumstances that the researcher deems unsuitable for the patient to participate in this study.",{"count":184,"type":21},26,[24],"Evaluation of the effectiveness and safety of laparoscopic assisted breast resection with preservation of nipple and areola, combined with chest muscle anterior prosthesis and patch for immediate one-step breast reconstruction and concurrent autologous fat transplantation in a prospective study",[28],[165,189,166,190],"Endoscopic technology","Autologous fat transplantation",{"date":146,"type":39},{"date":193,"type":39},"2024-10-30",{"date":195,"type":21},"2026-11",{"name":175,"class":129},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":205,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":4,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":47},"100593395","phase-2-hormonal-receptor-hr-positive-her2-negative-breast-cancer-patients-treated-with-preoperative-elacestrant-and-pulsar-radiotherapy-100593395","NCT07005882","Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy","Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Adaptive Radiotherapy: a Phase II Study (HELP Trial)","HELP","Inclusion Criteria:\n\n1. Histologically proven HR-positive, HER2-negative BC\n2. Clinical disease stage II-III\n3. Post-menopausal female patients or male patients\n4. Eligible for neoadjuvant treatment and subsequent surgery\n5. No contraindication to MRI\n6. Patient able to understand and follow instructions during the trial\n7. Patient able and willing to give written informed consent, signed and dated\n8. Patient aged at least 50 years old\n9. Patient with tumor accessible for biopsy and surgery\n10. Patient with adequate bone marrow function at Screening, confirmed at Baseline, including:\n\n    1. ANC ≥ 1.5 × 109\u002FL; patients with documented benign cyclical neutropenia are eligible if white blood cell count is ≥ 1.5 × 109\u002FL, with ANC ≥ 1.0 × 109\u002FL, leukocytes ≥ 4.0 × 109\u002FL, and lymphocytes ≥ 0.6 × 109\u002FL;\n    2. platelets ≥ 100 × 109\u002FL;\n    3. hemoglobin ≥ 9 g\u002FdL (may have been transfused);\n11. International Normalized Ratio (INR) \\\u003C 1.5×Upper Limit of Normal (ULN); patients treated with vitamin K antagonist are eligible if INR \\\u003C 3\n12. Patient with adequate hepatic function at Screening, confirmed at Baseline, defined by:\n\n    a. total bilirubin level ≤1.5×ULN; patients with documented Gilbert disease are allowed if total bilirubin ≤3×ULN; aspartate aminotransferase (AST) level ≤2.5×ULN, and alanine aminotransferase (ALT) level ≤2.5×ULN,\n13. Patient with adequate renal function at Screening, confirmed at Baseline, defined by eGFR ≥ 30 mL\u002Fmin using 2021 CKD-EPI creatinine equation\n14. Patient with Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n15. Life expectancy of at least 12 months according to the Investigator's judgement\n\nExclusion Criteria:\n\n* 1\\. Patients with stage IV disease 2. Patients with a history of any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, based on the Investigator's judgement, provides a reasonable suspicion of a disease or condition that contraindicates the use of RT and\u002For Elacestrant or that might affect the interpretation of the trial results or render the patient at high risk for treatment complications.\n\n  3\\. Patients with any significant co-morbidity which, according to the Investigator's judgement, makes patient compliance to trial conditions unlikely.\n\n  4\\. Patients with previous malignant disease (other than the tumor disease for this trial) within the last five (5) years (except adequately treated non-melanoma skin cancers and carcinoma in situ of skin, bladder, cervix, colon\u002Frectum, breast, or prostate) unless a complete remission without further recurrence was achieved at least two (2) years prior to Screening, and the patient is deemed to have been cured with no additional therapy required or anticipated to be required.\n\n  5\\. Patients with a history of uncontrolled intercurrent illness. 6. Patients with a known prior hypersensitivity or contraindications to Elacestrant or any component in its formulations.\n\n  7\\. Patients with severe acute or chronic medical conditions, including:\n  1. Immune colitis\n  2. Inflammatory bowel disease\n  3. History of severe vomiting or diarrhea not having resolved to Grade 1 at Baseline\n  4. Immune pneumonitis\n  5. Pulmonary fibrosis\n  6. Psychiatric conditions including recent (within the last year) or active suicidal ideation or behavior\n  7. Laboratory abnormalities that may increase the risk associated with trial participation or trial treatment administration or may interfere with the interpretation of trial results and, in the judgement of the Investigator, would make the patient inappropriate for entry into this trial.\n\n     8\\. Patients with a history of small intestine resection surgery or other major gastrointestinal surgery.\n\n     9\\. Patients with an active infection requiring systemic therapy with antibiotics (at both Screening and Baseline).\n\n     10\\. Patients with a known history of human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome or multi-drug-resistant gram-negative bacteria.\n\n     11\\. Patients with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at Screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody Screening test positive).\n\n     12\\. Patients with increased anesthesiological risk (e.g. known or predicted difficult airway) if general anesthetic is required.\n\n     13\\. Premenopausal patients (defined as any woman who is not surgically sterile with a hysterectomy and\u002For bilateral oophorectomy or \\>12 months of amenorrhea and at least 50 years of age) 14. Patients aged less than 50 years old. 15. Patients with a known history of drug\u002Fsubstance abuse. 16. Patients participating in any other clinical trial within 30 days before Screening.\n\n     17\\. Patients receiving any other treatment that, in the opinion of the Investigator, might interfere with the trial.\n\n     18\\. Concomitant use of strong or moderate CYP3A4 inhibitors should be avoided and an alternative concomitant medicinal product with no or minimal potential to inhibit CYP3A4 should be considered.\n\n     19\\. Concomitant use of strong or moderate CYP3A4 inducers should be avoided and an alternative concomitant medicinal product with no or minimal potential to induce CYP3A4 should be considered.\n\n     20\\. Patients with a current drug or substance abuse. 21. Patients receiving chronic concurrent therapy within two (2) weeks before the trial treatment or expected therapy during the trial treatment period with:\n\n  \u003C!-- -->\n\n  1. Corticosteroids (except systemic corticosteroids up to 10 mg prednisolone or equivalent daily dose).\n  2. Immunosuppressive agents.\n  3. Antibiotics.\n  4. Any other anticancer therapy or concurrent anticancer treatment. 22. Patients who are unable to understand the protocol requirements, instructions and trial-related restrictions, the nature, scope, and possible consequences of the trial.\n\n     23\\. Patients who are unlikely to comply with the Protocol requirements, instructions and trial-related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the trial.\n\n     24\\. Patients with legal incapacity or limited legal capacity. 25. Patients with any condition which results in an undue risk for the patient during the trial participation according to the Investigator.","50 Years",{"count":207,"type":21},21,[89],"This is a proof-of-concept phase II trial to assess the safety (as primary endpoint) and clinical efficacy of neoadjuvant therapy with Elacestrant and PULSAR.\n\nThe study will enroll 21 postmenopausal patients with early HR+ HER2- node positive BC, clinically staged II-III. Patients will receive Elacestrant 345 mg orally once daily for 24 weeks and PULSAR on the MRI-based breast gross tumor volume (GTVt), consisting of 10 Gy \"pulse\" every 4 weeks for a maximum of 5 or less in case of radiologic complete response.\n\nSurgery will be planned 24 weeks after Elacestrant initiation and at least 2 weeks from the last pulse and will be performed as per recommended clinical practice. Patients will then receive adjuvant systemic therapy as per standard of care and postoperative RT to the locoregional lymph nodes in case of nodal residual disease, if indicated.",[28,211,212,213],"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","HR+\u002FHER2- Breast Cancer","Radiation Therapy","2025-06-03",{"date":216,"type":39},"2025-06-05",{"date":218,"type":21},"2025-09-01",{"date":220,"type":21},"2028-03-01",{"name":222,"class":46},"Azienda Ospedaliero-Universitaria Careggi",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":138,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":47},"100584093","ultrasound-guided-multilevel-erectorspinae-plane-block-versus-thoracic-epidural-analgesia-for-prevention-of-post-mastectomy-pain-syndrome-for-breast-cancer-patients-100584093","NCT06884852","Ultrasound-guided Multilevel Erectorspinae Plane Block Versus Thoracic Epidural Analgesia for Prevention of Post Mastectomy Pain Syndrome for Breast Cancer Patients","Inclusion Criteria:\n\n* Female patients age ≥ 18 years and ≤ 65 Years.\n* Type of surgery; Modified Radical Mastectomy (MRM)\n* Physical status ASA II, III.\n* Body mass index (BMI): \\> 20 kg\u002Fm2 and \\\u003C 35 kg\u002Fm2.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Allergy or a contraindication to the drug used in the study, e.g. local anesthetics, opioids.\n* History of psychological disorders.\n* History of chronic pain.\n* Contraindication to regional anesthesia e.g. sepsis, peripheral neuropathies and coagulopathy.\n* Advanced chronic renal disease, which is defined as a chronic kidney disease (CKD) in which there is a severe reduction in glomerular filtration rate (GFR \\\u003C 30 ml\u002Fmin) and includes stages 4 and 5 of the CKD classification.\n* Decompensated cirrhosis, which is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or variceal hemorrhage.\n* Severe heart disease which is defined as NYHA class iii (moderate symptoms with less than normal activity, marked limitation of function status) or NYHA class IV (severe symptoms with features of heart failure with minimal activity or at rest and severe limitation of functional status)\n* Severe lung disease which includes oxygen saturation of blood less than 92%, RR more than 20, FEV1\u002FFVC ratio less than 60%.\n* Pregnancy.",{"count":230,"type":21},44,[24],"The aim of this study is to compare the analgesic efficacy of multilevel erector spinae plane block (ESPB) vs thoracic epidural in modified radical mastectomy (MRM) regarding duration of analgesia, postoperative opioid consumption, effect on intraoperative fentanyl consumption, postoperative numerical pain rating scale and quality of life for the next 6 months.",[234,235,236,237,238,28],"Ultrasound","Multilevel Erector Spinae Plane Block","Thoracic Epidural Analgesia","Post Mastectomy","Pain Syndrome","2025-05-18",{"date":241,"type":39},"2025-05-21",{"date":243,"type":39},"2025-03-20",{"date":245,"type":21},"2026-03-01",{"name":247,"class":46},"National Cancer Institute, Egypt",{"id":249,"slug":250,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":54,"minAge":254,"maxAge":85,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":47},"100589273","effects-of-two-strength-exercise-programs-on-upper-limb-functionality-in-breast-cancer-100589273","NCT06952270","Effects of Two Strength Exercise Programs on Upper Limb Functionality in Breast Cancer","Inclusion Criteria:\n\n* Pathological diagnosis of breast cancer.\n* Patients who have undergone a mastectomy, including unilateral, total breast, or breast-conserving surgery.\n* Postoperative chemotherapy or radiotherapy as required.\n* No other malignant tumors in the last 5 years.\n* Absence of contraindications related to physiotherapy or physical exercise.\n* Willingness to participate in the study and sign the informed consent form.\n\nExclusion Criteria:\n\n* Metastasis to other organs and tissues (liver, kidney, lung, brain, etc.) that prevent participation in the exercise program.\n* Underlying heart disease, cerebrovascular disease, or mental illness that impairs proper execution of the exercise program.\n* Pre-existing shoulder pathology before surgery.\n* Inability to understand the plyometric exercise program.","25 Years",{"count":256,"type":21},24,[24],"The goal of this experimental study is to evaluate the effect of a therapeutic exercise program based on upper limb plyometric exercises in breast cancer patients and breast cancer survivors to determine changes in upper limb functionality.\n\nThe main question it aims to answer is: Does upper limb plyometric strength exercise improve upper limb dysfunctions in breast cancer patients and survivors? The researchers will compare the effects of plyometric exercise with the effects of strength training exercise to determine whether plyometric exercise improves shoulder dysfunctions in breast cancer patients and survivors.\n\nParticipants from the Pontevedra group will undergo the intervention using plyometric exercise (Experimental Group), while those from the Vigo group will perform strength training exercise (Control Group). They will complete two sessions per week for six weeks. Outcome variables related to upper limb functionality will be assessed at baseline and after the intervention.",[260,66,28,261],"Breast Cancer Survivor","Breast Cancer - Female",[31,263,264,265,266,267,268],"plyometric exercise","upper limb","strength training","exercise","Recovery of Function","clinical trial","2025-04-26",{"date":271,"type":39},"2025-04-30",{"date":273,"type":21},"2025-05-02",{"date":275,"type":21},"2025-07",{"name":277,"class":46},"University of Vigo",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":283,"acronym":4,"eligibilityCriteria":284,"healthyVolunteers":11,"sex":54,"minAge":285,"maxAge":138,"enrollmentInfo":286,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":304},"100572796","effects-of-sensorimotor-training-with-chemotherapy-induced-peripheral-neuropathy-in-breast-cancer-patients-100572796","NCT06737926","Effects of Sensorimotor Training With Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients","Effects of Sensorimotor Training on Pain Intensity, Perceived Balance Confidence and Functional Exercise Capacity With Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients","Inclusion Criteria:\n\n* Females with invasive ductal carcinoma, stages I-III\n* Age ranged between 30-65 years\n* 3-6 months post breast cancer diagnosis\n* Those who have completed chemotherapy treatment and are medically stable\n* CIPN symptoms as subjectively assessed by FACT\u002FGOG-Ntx. Score ranges from 0-44 (5). 0 - 10: Minimal or no neurotoxicity symptoms, 11 - 20: Mild neurotoxicity symptoms, 21 - 30: Moderate neurotoxicity symptoms, 31 - 40: Severe neurotoxicity symptoms, 41 - 44: Very severe neurotoxicity symptoms\n* For balance testing Fullerton Advanced Balance (FAB) scale was used. 0-19 = high risk of falls, 20-29 = moderate balance impairment, 30-40 = good balance. The cut off value is ≤ 25\u002F40 Points.\n* Objective neurological testing such as Achilles and patellar tendon reflexes (1 = agile, 2 = weak, 3 = missing), peripheral deep sensitivity (0=no sensitivity to 8=highest sensitivity), light touch perception (symmetrical or impaired), sense of position (1 = position recognized, 2 = only position of knee recognized, and 3 = no recognition) and lower leg strength (0 = no activity to 5 = normal force) rated on a Likert-scale\n\nExclusion Criteria:\n\n* Women with additional types of cancer besides breast cancer\n* Chronic medical conditions such as poorly controlled diabetes (6)\n* Significant neurological (multiple sclerosis) or cardiopulmonary disease (myocardial infarction \\\u003C 3 months) that may affect performance (6)\n* Unstable bone metastasis","30 Years",{"count":256,"type":21},[24],"Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a prevalent and clinically relevant side effect of chemotherapy in breast cancer patients. It occurs in 30-70% of cases. It can cause various sensory and motor symptoms. Specific exercise interventions have proven promising to target relevant symptoms. Therefore, the objective of this study is to determine the effects of Sensorimotor training on pain intensity, perceived balance confidence, and functional exercise capacity with chemotherapy-induced peripheral neuropathy in breast cancer patients.",[290,28],"Chemotherapy Induced Peripheral Neuropathy",[66,63,292,293,294],"Postural Balance","Sensorimotor Neuropathy","Exercise","2024-12-12",{"date":297,"type":39},"2024-12-17",{"date":299,"type":39},"2024-01-15",{"date":301,"type":21},"2024-12",{"name":303,"class":46},"Riphah International University",2,{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":314,"conditions":315,"keywords":319,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":334},"100568771","the-4d-picture-project-evaluating-metro-mapping-as-a-method-to-support-shared-decision-making-in-oncology-100568771","NCT06685562","The 4D PICTURE Project: Evaluating Metro Mapping As a Method to Support Shared Decision Making in Oncology","The 4D PICTURE Project - Design-based Data-driven Decision-support Tools: Producing Improved Cancer Outcomes Through User-Centered Research","Inclusion Criteria:\n\n* Adult (\\>18 years) (either being the patient or the informal caregiver in the care path)\n* Prostate cancer, breast cancer or melanoma cancer\n* Able to provide consent\n* Able to speak Dutch, Danish, Spanish, Catalan\n\nExclusion Criteria:\n\nA potential subject who does not meet any of the above criteria will be excluded from participation in this study. There are no further specified exclusion criteria.",{"count":313,"type":21},500,"The goal of this observational study is to evaluate the impact of MetroMapping (a service design methodology) on Shared Decision Making in cancer care paths. The goal is to improve Shared Decision Making and make cancer care paths less overwhelming. The study will include adult participants (older than 18 years) with breast, prostate and melanoma cancers. The main question is How does the implementation of MetroMapping improve Shared Decision Making in cancer care paths.\n\n500 patients, across the Netherlands, Spain, and Denmark, will be enrolled in a pre- and posttest phase. Including 100 breast cancer, 100 prostate cancer, and 50 melanoma patients per phase. To further understand patient experiences, the researchers will audio-record and transcribe the Shared Decision Making consultation of a subset of participants (10 per tumor type per country). A total of 120 audio-recordings across both study phases will be collected. In the post-test phase, a personal care path navigator will be created and the researchers will conduct interviews with 3 patients per care path and interviews with clinicians (12 per country, a total of 36) to assess their experiences with MetroMapping.\n\nThe study is a pre-test and post-test multiple methods design, gathering both quantitative and qualitative data across care paths in the Netherlands, Spain and Denmark. Quantitative data will be collected via electronic (Castor EDC \\& RedCap) and paper questionnaires. Participants will receive the first set of questionnaires, one week after their decision-making consult. Encompassing the following questionnaires (I-SHARE for perceived Shared Decision Making, Control Preferences Scale for the perceived roles in the actual decision, Decisions Made, Decisional Comfort Scale, SCIP B Information Provision, PEPPI-5 Perceived Efficacy in Patient-Physician Interactions, Trust in Oncologists, Health Literacy) and for the cost-effectiveness analysis for our partner (UMIT TIROL) the EORTC QLU C10-D and EQ-5D5l will be added to assess utilities. In the post-test participants will receive the second set of questionnaires, 6 months after the first set of questionnaires. This set encompasses (Healthcare Integration INTEGrate, Person Centered Coordinated Care Experiences P3CEQ, Decisional Regret Scale, Trust in Oncologists, EORTC QLU-C10D, EQ-5D5L, Productivity Cost Questionnaires.\n\nThis study includes a pre-implementation comparison group, and results will be compared with post-implementation outcomes.\n\nParticipants will complete the questionnaires and provide demographic and clinical data (consent for sharing medical file is asked) and an audio-recording of their consultation will be made. Participants in the post-phase will participate in interviews about their experiences with the implementation of MetroMapping.\n\nThe audio-recordings will be transcribed and analyzed using the OPTION and 4SDM coding instruments. Data will be analyzed using both univariate and multivariate statistical methods. Transcript of audio-recordings will be analyzed using thematic analysis and the coding instruments.",[28,316,317,318],"Melanoma Cancer","Prostate Cancer","Supportive Care in Cancer",[320,321,322,323,324],"MetroMapping","Shared Decision Making","Oncology","Service design","care path redesign","2024-11-11",{"date":327,"type":39},"2024-11-12",{"date":329,"type":39},"2023-12-20",{"date":331,"type":21},"2026-05-20",{"name":333,"class":46},"Leiden University Medical Center",3,{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":54,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":47},"100399362","coping-after-breast-cancer---a-randomized-clinical-trial-with-two-digital-interventions-100399362","NCT04480203","Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions","Coping After Breast Cancer - CABC - Stressmestring Etter Brystkreft - SEB","CABC","Inclusion Criteria:\n\n* first occurrence breast cancer diagnosed from Jan 1, 2020\n* non-metastatic cancer stage 0-III\n\nInvasive tumors must be:\n\n* HER2 positive (regardless of ER, PR) or\n* ER negative\n* (may later include other ER+ if not conflict with recruitment for EMIT\u002FOPTIMA)\n\nExclusion Criteria:\n\n* None","20 Years","69 Years",{"count":346,"type":21},390,[24],"1. Breast cancer patients and age-matched controls are first invited to answer questions on HRQoL.\n2. Among responding breast cancer patients, a subset are invited in a randomized clinical trial with two digital interventions for cancer stress management, cognitive based stress management (CBSM) and mindfulness based intervention (MBI), as well as a control group.\n3. The goal is to determine whether digital CBSM or MBI can effectively reduce stress levels as compared to a control group. Second, whether these interventions can improve HRQoL (or avoid onset of HRQoL problems) for patients with breast cancer, compared to a control group.",[28,350],"Health, Subjective",[352,353],"Health Related Quality of Life","Stress management intervention","2022-02-11",{"date":356,"type":39},"2022-03-02",{"date":358,"type":39},"2021-01-15",{"date":360,"type":21},"2035-12-31",{"name":362,"class":129},"Norwegian Institute of Public Health"]